SNY Price Prediction Next Week
Technical Analysis
- RSI (14) at 62.24 indicates bullish momentum but not yet overbought
- MACD shows positive trend with 0.94 value, though slight bearish divergence (-0.09 histogram)
- Price trading above all major moving averages (5,10,20,60,200-day SMAs)
- Bollinger Bands show price near upper band (55.58) with 0.71 position, suggesting moderate upward momentum
News Impact
- Positive Phase 2b study results for duvakitug treatment presented with Teva
- Strategic sale of 50% stake in consumer healthcare business Opella to CD&R
- FDA priority review acceptance for Dupixent to treat bullous pemphigoid
Price Prediction (Next Week) Target Ranges:
- Support: $53.35 (Fibonacci S1)
- Resistance: $54.78 (Fibonacci R1)
- Extended resistance: $55.22 (Fibonacci R2)
Recommendation: BUY Entry: $54.47 (current price) Target: $55.20 Stop Loss: $53.30
Rationale:
- Strong technical indicators showing upward momentum
- Positive catalysts from FDA priority review and clinical trial results
- Price consolidating above key moving averages with room for upside
- Multiple support levels provide downside protection
SNY Similar Chart Price Prediction
The price of SNY is predicted to go up -9.7%, based on the high correlation periods with SSRM. The similarity of these two price pattern on the periods is 97.82%.
SNY
SSRM
Down: -9.7%Similarity: 97.82%
SNY Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
SNY Price Forecast($)
Potential Return(%)
2025
48.320
0.350
2026
100.000
84.030
2027
110.000
102.430
2028
120.000
120.830
2029
85.000
56.420
2030
120.000
120.830
What is SNY stock price prediction 2025 ?
What is SNY stock price prediction 2026 ?
What is SNY stock price prediction 2027 ?
What is SNY stock price prediction 2028 ?
What is SNY stock price prediction 2029 ?
What is SNY stock price prediction 2030 ?
SNY Revenue Forecast
SNY EPS Forecast
SNY FAQs
What is bull’s view on SNY?
What is bear's view on SNY?
What is SNY revenue forecast for next quarter？
What is SNY eps forecast for next quarter？
SNY VS S&P500
Sanofi is launching immunology drug Dupixent in several indications and the drug holds strong pricing power and major blockbuster potential across several indications.
Sanofi's strong entrenchment in rare-disease drugs should translate into steady pricing power as payers tend not to push back on pricing in these areas.
With a wide product offering in vaccines, consumer health and insulins, Sanofi is well positioned for the fast-growing emerging markets.
